Avalo Therapeutics (NASDAQ:AVTX) Insider Sells $13,580.00 in Stock

Avalo Therapeutics, Inc. (NASDAQ:AVTX) insider Mittie Doyle sold 679 shares of the firm’s stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $20.00, for a total value of $13,580.00. Following the sale, the insider owned 51,776 shares of the company’s stock, valued at $1,035,520. The trade was a 1.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mittie Doyle also recently made the following trade(s):

• On Monday, July 27th, Mittie Doyle sold 1,000 shares of Avalo Therapeutics stock. The shares were sold at an average price of $20.00, for a total value of $20,000.00.
• On Tuesday, June 23rd, Mittie Doyle sold 1,450 shares of Avalo Therapeutics stock. The shares were sold at an average price of $18.00, for a total value of $26,100.00.

Avalo Therapeutics Price Performance

NASDAQ AVTX opened at $19.00 on Friday. The firm has a market capitalization of $1.02 billion, a price-to-earnings ratio of -4.35 and a beta of 0.78. The company has a 50 day simple moving average of $19.10 and a 200-day simple moving average of $16.92. Avalo Therapeutics, Inc. has a 52-week low of $9.54 and a 52-week high of $24.27.

Avalo Therapeutics (NASDAQ:AVTX) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.83) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.25). On average, analysts predict that Avalo Therapeutics, Inc. will post -2.59 EPS for the current year.

Institutional Trading of Avalo Therapeutics

Large investors have recently made changes to their positions in the stock. Braidwell LP bought a new position in shares of Avalo Therapeutics in the 2nd quarter valued at approximately $30,107,000. Orbimed Advisors LLC lifted its holdings in Avalo Therapeutics by 39.5% in the 3rd quarter. Orbimed Advisors LLC now owns 1,349,300 shares of the company’s stock worth $17,150,000 after purchasing an additional 382,300 shares during the last quarter. Affinity Asset Advisors LLC boosted its position in Avalo Therapeutics by 27.6% during the first quarter. Affinity Asset Advisors LLC now owns 1,340,840 shares of the company’s stock worth $20,019,000 after purchasing an additional 289,786 shares during the period. Nantahala Capital Management LLC boosted its position in Avalo Therapeutics by 24.1% during the third quarter. Nantahala Capital Management LLC now owns 1,235,000 shares of the company’s stock worth $15,697,000 after purchasing an additional 240,000 shares during the period. Finally, Caligan Partners LP grew its holdings in Avalo Therapeutics by 5.8% during the fourth quarter. Caligan Partners LP now owns 881,533 shares of the company’s stock valued at $16,009,000 after purchasing an additional 48,200 shares during the last quarter. Institutional investors own 87.06% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on the company. HC Wainwright lowered their target price on Avalo Therapeutics from $35.00 to $30.00 and set a “buy” rating on the stock in a research note on Friday, August 7th. Weiss Ratings raised Avalo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Leerink Partners assumed coverage on Avalo Therapeutics in a report on Monday, July 6th. They set an “outperform” rating and a $38.00 price target for the company. Wedbush lowered their price target on Avalo Therapeutics from $40.00 to $34.00 and set an “outperform” rating for the company in a research note on Thursday, May 14th. Finally, BTIG Research restated a “buy” rating and issued a $58.00 price objective on shares of Avalo Therapeutics in a report on Tuesday, June 16th. Thirteen research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $45.10.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.